Results 51 to 60 of about 451,267 (297)

Assessing variation among the national essential medicines lists of 21 high-income countries: a cross-sectional study

BMJ Open, 2021
Objective Essential medicines lists have been created and used globally in countries that range from low-income to high-income status. The aim of this paper is to compare the essential medicines list of high-income countries with each other, the WHO’s ...
Nav Persaud, Michael Sergio Taglione
doaj   +1 more source

The human right to medicines [PDF]

, 2008
This article considers the component of the right to the highest standard of health that relates to medicines, including essential medicines. Using the right-to-health analytical framework that has been developed in recent years, the first section ...
Hunt, PH, Khosla, R
core  

Study protocol for a cluster-randomized controlled trial of an NCD access to medicines initative: Evaluation of Novartis Access in Kenya [PDF]

, 2016
INTRODUCTION: Novartis recently launched Novartis Access, an initiative to provide a basket of reduced price medicines for non-communicable diseases (NCDs) to be sold through the public and private nonprofit sectors in programme countries.
Ashigbie, Paul G., Laing, Richard, Onyango, Monica A., Rockers, Peter C., Vian, Taryn, Wirtz, Veronika J.   +5 more
core   +1 more source

A PRSZT Registry Analysis of Prognostic Factors Influencing Survival and Relapse Rates After Second Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT A second allogeneic (allo‐)hematopoietic stem cell transplantation (HSCT2) is a potential curative option for pediatric patients with acute lymphoblastic leukemia (ALL) following relapse after first allogeneic transplantation (HSCT1), but its efficacy is limited by high relapse rates and transplant‐related toxicity in highly pretreated ...
Ava Momm, Imme Haubitz, Rita Beier, Martin Zimmermann, Andrej Lissat, Peter Bader, Matthias Eyrich, Jan‐Henning Klusmann, Matthias Wölfl, Paul‐Gerhardt Schlegel, Verena Wiegering   +10 more
wiley   +1 more source

Submission to the United Nations Secretary General's High Level Panel on Access to Medicines [PDF]

, 2016
Much of the current debate on health care goals, medical innovation and trade rules focuses on the misalignment between the need to provide incentives to innovation – mainly through a tight intellectual property (IPR) regime – and the resulting negative ...
Kale, Dinar, Mackintosh, Maureen, Orsenigo, Luigi, Simonetti, Roberto   +3 more
core  

Impact of Universal Health Insurance Coverage in Thailand on Sales and Market Share of Medicines for Non-Communicable Diseases: an Interrupted Time Series Study [PDF]

, 2013
Objective: In 2001, Thailand implemented the Universal Coverage Scheme (UCS), a public insurance system that aimed to achieve universal access to healthcare, including essential medicines, and to influence primary care centres and hospitals to use ...
Garabedian, Laura Faden, Ratanawijitrasin, Sauwakon, Ross-Degnan, Dennis, Stephens, Peter, Wagner, Anita Katharina   +4 more
core   +1 more source

Evaluation of the Utility of Baseline Echocardiogram in Patients With Standard Risk Precursor B‐Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
Abstract Background A routine baseline echocardiogram is often obtained prior to anthracycline administration in children with cancer. The utility of baseline echocardiogram is unclear in patients with standard risk B‐cell acute lymphoblastic leukemia (SR B‐ALL) as their anthracycline cumulative dose is low.
Ziyad Alrajhi, Alice Pozza, Luc Mertens, Adam Paul Yan, Sarah Alexander   +4 more
wiley   +1 more source

Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal [PDF]

, 2015
© 2015 Brhlikova et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium ...
A Abdo-Rabbo, AH Meshkini, Allyson M. Pollock, B Shakya, B Shrestha, DA Grimes, DDA, E Toledo, ES Pinheiro, GAO, H Dixit, HSSP, I Harper, Ian Harper, J Abraham, J-M Guimier, K Losse, K Morimoto, K Timmermans, M Santhosh, Madhusudan Subedi, MHP, Nabin Rawal, P Brhlikova, P Trouiller, P Trouiller, PEPFAR, Petra Brhlikova, PG Mujinja, S Budhathoki, S Chaudhuri, S Hill, S Palaian, Samita Bhattarai, SAWTEE, Thapa, UNCTAD, UNIDO, W Kaplan, WA Kaplan, WHO, WHO, WHO, WHO, WHO, WHO, WHO, WHO WHO   +47 more
core   +1 more source

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High‐Dose Chemotherapy With Autologous Hematopoietic Stem‐Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Although most malignant germ cell tumors (GCTs) are highly curable with cisplatin‐based therapy, options for patients with multiply relapsed/refractory disease remain limited. For this population, we report the first pediatric use of gemcitabine, docetaxel, melphalan, and carboplatin (GemDMC) as part of sequential cycles of high‐dose ...
Maria Frost, Olayinka Okeleji, Amr Elgehiny, Douglas Harrison, Cynthia Herzog, Jeremy Connors, Demetrios Petropoulos, Priti Tewari, Dristhi Ragoonanan, Yago Nieto, Irtiza N. Sheikh   +10 more
wiley   +1 more source

The impact of the Medicines Control Council backlog and fast-track review system on access to innovative and new generic and biosimilar medicines of public health importance in South Africa [PDF]

, 2016
The fast-track registration policy of the South African National Department of Health allows for rapid registration of new medicines of public health importance and of all medicines on the Essential Medicines List, most of which are generics. No limit is
Leng, HMJ, Pollock, AM, Sanders, D
core   +3 more sources